Olesen O V, Linnet K
Department of Biological Psychiatry, Psychiatric Hospital, Aarhus University Hospital, Risskov, Denmark.
J Chromatogr B Biomed Sci Appl. 1997 Sep 26;698(1-2):209-16. doi: 10.1016/s0378-4347(97)00302-2.
A HPLC method was developed for determination of risperidone and its therapeutically active main metabolite 9-hydroxyrisperidone in serum. After a single-step liquid-liquid extraction the analytes were separated on a C18 column and measured by UV detection at 280 nm. Inter-day coefficient of variation was <7% for both compounds at serum levels occurring in patients treated with ordinary doses. Studies of analytical interference showed that the most commonly coadministered antidepressants and benzodiazepines did not interfere. Some conventional low dose neuroleptics and clozapine did interfere, but this is of minor importance, because risperidone is intended as an alternative to these drugs.
建立了一种HPLC方法，用于测定血清中的利培酮及其具有治疗活性的主要代谢物9-羟基利培酮。经过一步液-液萃取后，分析物在C18柱上分离，并通过280nm的紫外检测进行测定。在接受常规剂量治疗的患者血清水平下，两种化合物的日间变异系数均<7%。分析干扰研究表明，最常联合使用的抗抑郁药和苯二氮䓬类药物不会产生干扰。一些传统低剂量抗精神病药物和氯氮平确实会产生干扰，但这并不重要，因为利培酮旨在作为这些药物的替代品。
